Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Carboplatin in Patients with Platinum-Resistant Epithelial Ovarian Cancer
2008-000878-20Phase 2Completed
- Sponsor
- Vejle Hospital
- Start
- Jun 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and carboplatin in epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC), sponsored by Vejle Hospital. Primary endpoint: Progression-free survival. Started Jun 2008; status: completed.
02
Drugs
bevacizumabcarboplatin
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2008-000878-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000878-20.